Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
781 to 800 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Epigenetic Regulation in Chromium-, Nickel- and Cadmium-Induced Carcinogenesis. | Cancers (Basel) | 2022 | 36497250 | PubTator, text mining | PubMed |
| The BRCAness Landscape of Cancer. | Cells | 2022 | 36497135 | PubTator, text mining | PubMed |
IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. | BMC Cancer | 2022 | 36494792 | PubTator, text mining | PubMed |
| Whole-Exome Sequencing Among Chinese Patients With Hereditary Diffuse Gastric Cancer. | JAMA Netw Open | 2022 | 36484990 | PubTator, text mining | PubMed |
| WIN Symposium 2022 - Abstract Poster Presentations. | J Immunother Precis Oncol | 2022 | 36483583 | PubTator, text mining | PubMed |
| Utility of Matrix Metalloproteinases in the Diagnosis, Monitoring and Prognosis of Ovarian Cancer Patients. | Cancer Manag Res | 2022 | 36474934 | PubTator, text mining | PubMed |
| The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. | Nat Genet | 2022 | 36456881 | PubTator, text mining | PubMed |
| The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk. | BMC Urol | 2022 | 36451132 | PubTator, text mining | PubMed |
| A rare mutation (p.F149del) of the NT5C3A gene is associated with pyrimidine 5'-nucleotidase deficiency. | Cell Mol Biol Lett | 2022 | 36434495 | PubTator, text mining | PubMed |
| Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma. | Cells | 2022 | 36428992 | PubTator, text mining | PubMed |
| RAD51 Is Implicated in DNA Damage, Chemoresistance and Immune Dysregulation in Solid Tumors. | Cancers (Basel) | 2022 | 36428789 | PubTator, text mining | PubMed |
| Genetic Characterization in High-Risk Individuals from a Low-Resource City of Peru. | Cancers (Basel) | 2022 | 36428697 | PubTator, text mining | PubMed |
| Feasibility Study and Clinical Impact of Incorporating Breast Tissue Density in High-Risk Breast Cancer Screening Assessment. | Curr Oncol | 2022 | 36421341 | PubTator, text mining | PubMed |
| Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations. | Cancer Manag Res | 2022 | 36411744 | PubTator, text mining | PubMed |
Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2. | Ecancermedicalscience | 2022 | 36405946 | PubTator, text mining | PubMed |
| Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers. | Breast Cancer Res | 2022 | 36401316 | PubTator, text mining | PubMed |
| Germline pathogenic variants associated with ovarian cancer: A historical overview. | Gynecol Oncol Rep | 2022 | 36388756 | PubTator, text mining | PubMed |
| Concurrent loss of MLH1, PMS2 and MSH6 immunoexpression in digestive system cancers indicating a widespread dysregulation in DNA repair processes. | Front Oncol | 2022 | 36387226 | PubTator, text mining | PubMed |
| Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment. | Front Oncol | 2022 | 36387205 | PubTator, text mining | PubMed |
| Barriers, interventions, and recommendations: Improving the genetic testing landscape. | Front Digit Health | 2022 | 36386046 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=40